INDUSTRY WATCH
The company ’ s leading therapeutic candidate , Tune-401 , has now been approved for clinical trials in both Hong Kong and New Zealand .
Tune Therapeutics receives approval to initiate clinical trial in Hong Kong for HepB Epigenetic Silencer
72 INTELLIGENTCIO APAC www . intelligentcio . com